title: [Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic study].
abstract: OBJECTIVE
  To study the clinicopathologic features and differential diagnosis of blastic plasmacytoid dendritic cell neoplasm.
  
  
  METHODS
  The clinical, morphology and immunophenotypic features were analyzed in 3 cases of blastic plasmacytoid dendritic cell neoplasm, with review of literature.
  
  
  RESULTS
  The pathologic changes of these tumors accorded with that of blastic plasmacytoid dendritic cell neoplasm, and they also had new characteristics, including lineage other than T, B, myeloid and NK cells, and immunophenotypes of CD56(+) CD4(-) CD123(+) TdT(+) CD43(+) CD68(+) , CD56(+) CD4(+) CD123(-) TdT(+) CD43(+) CD68(-) and CD56(+) CD4(+) CD123(-/+) TdT(-) CD43(+) CD68(+) in the 3 cases, respectively. Bone marrow involvement was found 5 years later in case 1, and was then stable after chemotherapy; case 2 and case 3 were died 5 and 2 months after diagnosis, respectively.
  
  
  CONCLUSIONS
  Blastic plasmacytoid dendritic cell neoplasm is a heterogeneous group of lymphoproliferative disorders, with different clinical, morphologic and immunophenotypic features.
authors.affiliation: Department of Pathology, Xinjiang Medical University First Hospital, Urumqi 830054, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Sang
authors.forename: Chao-fu
authors.initials: CF
authors.lastname: Wang
authors.forename: Yu-fan
authors.initials: YF
authors.lastname: Cheng
authors.forename: Xia
authors.initials: X
authors.lastname: Liu
authors.forename: Xin-xia
authors.initials: XX
authors.lastname: Li
authors.forename: Abulajiang
authors.initials: A
authors.lastname: Gulinar
authors.forename: Jun-zhi
authors.initials: JZ
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D019002:CD56 Antigen / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use; D003713:Dendritic Cells / Q000378:metabolism / Q000473:pathology*; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D053650:Interleukin-3 Receptor alpha Subunit / Q000378:metabolism; D007951:Leukemia, Myeloid / Q000378:metabolism / Q000473:pathology; D054391:Lymphoma, Extranodal NK-T-Cell / Q000378:metabolism / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000378:metabolism / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D019002:CD56 Antigen; C115022:IL3RA protein, human; D053650:Interleukin-3 Receptor alpha Subunit; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone